Can I see a nurse prescriber instead of my GP for ongoing prescriptions?

Designated nurse prescribers work collaboratively with GPs and nurse practitioners rather than replacing them — they do not require GP supervision for each patient encounter, but their role is designed to complement general practice rather than substitute for it. The settings where they are most likely to improve your access are aged care facilities, palliative care, rural and remote communities, mental health services, and chronic disease management programs where they are already embedded in the care team. For most patients in metropolitan areas with good GP access, the change is less immediately visible but contributes to a more integrated care model overall.

Is this the same as pharmacist prescribing?

No — these are entirely different roles. Pharmacist prescribing expansions (currently live in various forms across Australian states) allow pharmacists to supply medicines for certain conditions without a prescription from a medical or nursing professional. Designated nurse prescribers are registered nurses who have completed additional postgraduate training and clinical mentorship and are formally endorsed by the Nursing and Midwifery Board to prescribe from within their scope. The October change is specifically about adding PBS subsidy access to nurse prescriptions that were already legally valid — patients were previously paying full private cost for the same medications a nurse prescribed.

Nurse prescribers can access PBS from October — what patients need to know

What just happened

New legislation quietly passed on 2 July 2026 will expand access to PBS-subsidised medicines from 1 October 2026 — not through GPs or nurse practitioners, but through a third professional group: designated registered nurse prescribers.

The change closes a gap that has existed since nurse prescribers were first established. Designated nurse prescribers have been legally able to prescribe Schedule 2–4 medicines and certain Schedule 8 controlled medicines, but their prescriptions have not attracted PBS subsidies. This means a patient receiving a prescription from a nurse prescriber was paying the full private cost of the medication, while the same script from a GP would cost $25 for a general patient or $7.70 for a concession cardholder. From October, that discrepancy ends.

The settings where this change is most likely to be felt are aged care facilities, palliative care services, rural and remote communities, mental health services, and chronic disease management programs — places where nurse prescribers are already embedded in care teams but where the inability to access PBS pricing has been a practical obstacle to their clinical effectiveness.

The both-and

Why this is a genuine improvement for access

The financial gap between private prescriptions and PBS-subsidised ones can be hundreds or even thousands of dollars per year for patients on regular medications. For an aged care resident, a palliative care patient, or a person managing a chronic condition in a rural area, access to PBS pricing is not a detail — it is the difference between affording ongoing medication management or not.

The change is also likely to make the nurse prescriber workforce more clinically effective. When a nurse prescriber embedded in a residential aged care facility can issue a PBS prescription without requiring a patient to be referred to a GP for every medication renewal, the practical result is faster access, fewer delays, and reduced burden on an already stretched general practice system. The patients most likely to benefit — frail older adults, people in the final stages of illness, people in remote areas — are also those for whom delays in medication access carry the highest clinical cost.

The qualification requirements for designated nurse prescribers are not trivial. They require three years’ full-time nursing experience, completion of an approved postgraduate qualification, six months of supervised clinical mentorship, and formal endorsement from the Nursing and Midwifery Board of Australia. This is a gate with real criteria, and it distinguishes designated nurse prescribers clearly from the broader nursing workforce.

What is still unresolved

The legislation has passed, but several important details are still being worked through. The specific list of PBS medicines that designated nurse prescribers will be able to prescribe has not yet been finalised. State and territory law changes for controlled substance prescribing — which vary across jurisdictions — are still in progress. How health services will implement the change in practice, and whether there are adequate numbers of trained nurse prescribers in the settings that need them most, remains to be seen.

These outstanding questions matter particularly for controlled medicines — Schedule 8 drugs including some opioids and certain psychotropics — where the state-level legislative alignment has to happen before the PBS access change fully translates into clinical practice. For patients in palliative care or pain management, this is where the real-world impact may arrive more slowly than the October date suggests.

The distinction from nurse practitioners matters

Designated nurse prescribers are sometimes confused with nurse practitioners, but they are a separate category with a different training pathway and a different scope. Nurse practitioners hold a master’s degree and can prescribe independently. Designated nurse prescribers work collaboratively with doctors and nurse practitioners — they do not require supervision for each individual patient encounter, but they operate within a collaborative framework rather than as fully independent prescribers.

This distinction is worth being clear about, because the clinical safeguards in the two models are different. The collaborative framework that designated nurse prescribers operate within is not a weakness — it is the design of the role, which is intended to extend the clinical team’s reach rather than replace any component of it.

It is also worth distinguishing this change from the pharmacist prescribing expansions that have attracted debate in the past 12 months. Pharmacist prescribing for conditions like uncomplicated urinary tract infections sits in a different regulatory and evidence framework entirely. The nurse prescriber PBS change is about access to subsidy for prescriptions that were already legally valid — it does not create new prescribing powers, only removes a financial barrier to existing ones.

My two cents

This is a quiet legislative change that is unlikely to make much difference to most people’s immediate experience, but will matter considerably for specific patient groups.

If you have an elderly parent in residential aged care — or if you live in a rural or remote area where general practice access is limited — it is worth understanding that from October, nursing staff with the right qualifications will be able to prescribe their PBS medications directly. That reduces delay and removes a practical barrier that has made nurse prescribers less clinically useful than their training should allow.

For most people in metropolitan areas with good general practice access, the change is less visible in practice. But the principle it reflects — that a qualified health professional should be able to do the full job their training equips them for, without unnecessary system friction — is the right one.

The October 2026 start date is worth watching. The medicine-specific PBS list and state-level controlled substance reforms are the remaining pieces. When those details land, they will determine how much of the promise this change actually delivers.

Verdict: yes — worth knowing about.

Sources cited

The Conversation — Nurses will soon be able to prescribe PBS drugs. Here’s what that means for you (July 2026). https://theconversation.com/nurses-will-soon-be-able-to-prescribe-pbs-drugs-heres-what-that-means-for-you-287165